Evaluating the safety of an immunotherapy drug for acute lymphoblastic leukemia
The purpose of this study is to evaluate the safety, efficacy and tolerability of subcutaneous (SC) blinatumomab for treatment of acute lymphoblastic leukemia and to determine the maximum tolerated dose and preliminary recommended phase 2 dose(s) of SC administered blinatumomab.